Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16330755 | 0.93 | ADK (0.47) | ADKHIF1ATP53STAT6SLC29A1 | |
| SCHEMBL16330700 | 0.89 | ADK (0.49) | ADKHIF1ATP53STAT6SLC29A1 | |
| SCHEMBL16330699 | 0.88 | ADK (0.44) | ADKHIF1ASLC29A1PRMT5 | |
| SCHEMBL16330696 | 0.86 | ADK (0.48) | ADKHIF1ATP53STAT6SLC29A1 | |
| SCHEMBL16330692 | 0.85 | HIF1A (0.54) | ADKHIF1ATP53STAT6 | |
| SCHEMBL16330685 | 0.82 | HIF1A (0.45) | ADKHIF1ATP53STAT6 | |
| SCHEMBL16330697 | 0.81 | ADK (0.49) | ADKHIF1ATP53STAT6SLC29A1 | |
| SCHEMBL16330758 | 0.81 | HIF1A (0.40) | ADKHIF1ATP53STAT6 | |
| SCHEMBL16330701 | 0.80 | ADK (0.46) | ADKHIF1ASLC29A1PRMT5METTL3 | |
| SCHEMBL16330684 | 0.78 | HIF1A (0.56) | ADKHIF1ATP53STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | ADK 104/4885HIF1A 922/4885TP53 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.